Buy CJC-1295 Without DAC 5mg Research Peptide OnlineCJC-1295 Without DAC Peptide IdentificationThis formulation delivers Modified GRF 1-29 (CJC-1295 without DAC) at 5mg per vial. The 29-amino-acid growth hormone-releasing factor analog incorporates DPP-IV-resistant modifications enabling acute GH secretion investigation in preclinical systems. The absence of Drug Affinity Complex permits study of short-duration hormone signaling patterns distinct from long-acting variants. Supplied as pharmaceutical-grade lyophilized powder.CJC-1295 Without DAC Mechanism of ActionUnmodified CJC-1295 engages GHRH receptor 1a signaling with immediate onset and natural metabolic clearance within hours, enabling concentration-dependent investigation of acute somatotroph responses. The peptide initiates growth hormone-releasing hormone receptor signal cascades, elevating intracellular cAMP in cell culture models and modulating GH secretion patterns in animal research. The shorter duration profile facilitates study of pulsatile versus chronic GH axis signaling distinctions.CJC-1295 Without DAC Published Research SummaryRaun et al. (2000) established GRF analog GHRH receptor pharmacology and DPP-IV peptidase resistance through amino acid substitutions. Bowers et al. (2003, Journal of Peptide Research) documented acute GH secretion kinetics with unmodified CJC-1295 versus extended-release formulations. Preclinical literature demonstrates utility in investigating acute GH-axis responses and pulsatile secretion modeling in controlled laboratory systems.CJC-1295 Without DAC 5mg Product Specifications & HandlingForm: Lyophilized powder, white/pale cream; Quantity: 5mg per vial; Storage: -20°C, desiccated, light-protected; Reconstitution: Sterile normal saline or bacteriostatic water; Stability: 24 months under specified storage conditions; Purity: >99% by HPLC analysis; Molecular weight: 3.4 kDa; Half-life: 2-3 hours in preclinical models.CJC-1295 Without DAC Research Use Only DisclaimerResearch use only. Not intended for human consumption, medical diagnosis, clinical treatment, disease mitigation, or therapeutic application. All described biological activities are based on controlled preclinical research. Institutional review board compliance and regulatory authorization required for laboratory use.
